Human height is a canonical complex trait, under tight genetic control with heritability of 80-90% ([@R1],[@R2]). Although rare variants with strong effects have been reported in families with monogenic forms of dwarfism or gigantism, the \~700 reported variants affecting height - which explain only about 16% of the observed heritability - are typically common alleles with modest effect sizes (average \<0.3 cm) (^[@R3],[@R4]^). Little is known about the impact of rare and founder variants on stature at a population level and whether they contribute to variation in height between populations. The founder Sardinian population is especially suitable to assess the impact of such variants. Although most of the common genetic variants present elsewhere in Europe also exist in Sardinia, the isolated island population is enriched for numerous variants that are very rare or absent elsewhere (^[@R5]^) and were not included in the commercial genotyping arrays or multi-population sequencing panels that are commonly used to characterize genetic variants through imputation (^[@R6]^).

We therefore used whole genome sequencing to investigate height in a large sample of Sardinians, who, with an average male stature of 168.5 cm (^[@R7]^), are among the shortest European populations.

We used whole genome sequencing (\~4x) of 2,120 Sardinians to construct a reference panel of \~17.6 million SNPs ([Supplementary Fig. 1a,b](#SD1){ref-type="supplementary-material"}) and carry out a genome wide association study (GWAS) for height. After stringent quality controls and imputation using a scaffold of 890,542 genotyped SNPs, 11,826,948 SNPs were assessed in 6,307 participants in the SardiNIA study, from villages in the Lanusei valley (^[@R1]^). The GWAS found two signals strongly associated with stature, one located in the *GHR* (5p12) and the other in the *KCNQ1* (11p15.5) genes, which encode the growth hormone receptor and a voltage-gated potassium channel, respectively ([Supplementary Fig. 1c](#SD1){ref-type="supplementary-material"}). Notably, their joint effect in the SardiNIA cohort is as large as that contributed jointly by the top 10 height associated alleles assessed in the GIANT meta-analysis\[^[@R4]^\] and by the top 5 when using the effect sizes observed in the replication set.

The first of these signals is rs121909358 (p=1.07×10^−10^, effect −0.64 s.d. corresponding to −4.2 cm, [Fig.1a](#F1){ref-type="fig"}, [Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). The height-reducing T allele is found on a single haplotype ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). It creates a loss of function termination codon (R61X) in *GHR*. The variant and its association with height would not have been detected without imputation from the Sardinian sequencing panel (imputation accuracy, RSQR=0.94, validated by direct genotyping) (^[@R6]^), as the variant is extremely rare outside of Sardinia (frequency \<1/60,000, ExAC Browser, [URLs](#FN3){ref-type="fn"}).

Homozygosity for this stop codon variant is one of several mutations in *GHR* known to cause Laron syndrome (LS) (OMIM\#262500); a rare autosomal recessive condition characterized by primary growth hormone insensitivity. Since the initial description (^[@R8]^), more than 250 LS cases have been reported (Orphanet, [URLs](#FN3){ref-type="fn"}), with the majority of patients identified in Maghrebi-Sephardic Jewish groups (^[@R9]^) and an isolated population of Spanish descent in Ecuador (^[@R10]^). The global estimated prevalence of LS is 1-9 per million (Orphanet, [URLs](#FN3){ref-type="fn"}) suggesting world-wide carrier frequencies of less than 0.01%. In contrast, we observed an unexpectedly high frequency of 0.87% for the R61X variant among 1,481 unrelated individuals from the SardiNIA cohort. Consistent with this frequency, 1 homozygous affected LS individual has been observed among the 10,721 inhabitants of the 4 villages in the Lanusei valley. The association of R61X with height was replicated in an independent Sardinian cohort of 5,314 individuals from an additional 6 villages ([Supplementary Note](#SD2){ref-type="supplementary-material"}), though its frequency and the effect size are estimated to be smaller (MAF= 0.46% in 857 unrelated individuals, p~one-tail~ =0.015, effect −0.31 s.d., corresponding to −1.89 cm).

Our results extend to the general population the evidence that *GHR* mutations affect height of heterozygous carriers ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}, ^[@R11],[@R12]^). In addition, 30% of the carriers from the SardiNIA study also showed limited elbow extension, which is very rare in unaffected individuals but characteristic of LS patients due to underdevelopment of the muscular system and an abnormal degree of humerus rotation ([Supplementary Table 2](#SD2){ref-type="supplementary-material"}, ^[@R8]^). Interestingly, among 2,120 sequenced Sardinians, we also found instances of two additional rare variants described to cause LS in Southern European and South American populations ([Supplementary Note](#SD2){ref-type="supplementary-material"}, [Supplementary Table 3](#SD2){ref-type="supplementary-material"}); however those variants were at frequencies too low in the SardiNIA cohort (MAF\<0.003) to assess phenotypic effects in heterozygotes.

The second GWAS signal in *KCNQ1* ([Fig. 1b](#F1){ref-type="fig"}) is complicated by the fact that it falls in a known tissue-specific imprinted gene cluster. Indeed, we found striking evidence that the association with short stature is maternally inherited ([Fig. 1](#F1){ref-type="fig"}, [Table 1](#T1){ref-type="table"}), with the strongest maternal effects at rs150199504 (MAF= 7.7%, p=5.6×10^−9^, maternal effect −0.315 s.d., corresponding to −1.83 cm), and no significant paternal effect (p=0.95) ([Table 1](#T1){ref-type="table"}, [Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). By directly typing one of the top associated variants, rs2075870, which also showed a modest albeit significant association with decreased height in \~90,000 individuals of European origin (^[@R13]^), we confirmed the association in the independent Sardinian cohort (p=3.6×10^−4^ for the maternal effect −0.22 s.d., corresponding to −1.17 cm and p=0.1 for paternal effect). The association signal spans 48Kb encompassing rs2075870 and 4 additional variants in LD with rs150199504 (pvalue \<1×10^−6^, r^2^\> 0.7) ([Fig. 1](#F1){ref-type="fig"}, [Table 1](#T1){ref-type="table"}) making it difficult to identify the causal variant (s).

However, we found that differences in allele frequencies and LD patterns among the variants in Sardinia compared to other populations provided a route to prioritize the list for the responsible variant(s) ([Fig. 2](#F2){ref-type="fig"}). Remarkably, among the SNPs in LD in Sardinia, we could exclude rs2075870, rs67004488, rs149658560 and rs12790610 as causal based on their frequencies, LD patterns and results from GWAS in other populations. In particular, these variants are common (MAF \~10%), in LD with each other (r^2^\>0.3) in South Asia, and yet no association of rs2075870 with height has been observed there (^[@R13]^). By contrast, among our core associated SNPs, the top variants rs150199504 and rs143840904 are in lower LD with rs2075870 and much rarer in South Asia (r^2^\<0.3 and MAF \<1.2 % and \<2.6% respectively) ([Fig. 2d](#F2){ref-type="fig"}) and thus association with height could be missed if they are not directly typed in very large sample sets. Hence, rs143840904 and especially our lead variant rs150199504 are plausible causal candidates.

To further assess their candidacy, we directly tested the 6 core associated variants in 19,053 individuals from 6 GWAS European cohorts, among which we expect more resolving power than in Sardinia due to lower LD in the region ([Fig. 2b, 2c](#F2){ref-type="fig"}). Among the 5 variants that passed quality checks, rs150199504 was again the most significantly associated and had the strongest effect in these samples as well (p=2.82×10^−4^, effect −0.243 s.d) -- even though it was the rarest of the five (MAF = 0.89 %). To a lesser extent significant association was also seen for rs143840904 (p=1.23×10^−3^, effect −0.145 s.d.), but was not observed for the 3 other variants ([Supplementary Table 4](#SD2){ref-type="supplementary-material"}). Interestingly, in a reciprocal conditional analysis, the effect of rs143840904 was completely accounted for by rs150199504 (p=0.24, effect −0.06 s.d.). By contrast residual association remained at rs150199504 after conditioning on rs143840904 (p=0.06, effect −0.172 s.d.). This further genetic evidence supports rs150199504 as the main driver of the association with decreased height at this locus. Suggestively, rs150199504 (and rs143840904) fall in a differentially methylated region (ENCODE, [URLs](#FN3){ref-type="fn"}), hinting at a possible effect on expression.

The maternal effect we observed for *KCNQ1* on height is consistent with the established monoallelic expression of maternal alleles at this imprinted locus (^[@R14]^). Furthermore, the observation that translocations and inversions disrupting the function of *KCNQ1* result in Beckwith-Wiedemann gigantism (^[@R15]^) suggests that, by inference, the short stature alleles reported here result in a gain of function.

*KCNQ1* variation has been implicated in several other traits, including platelet aggregation, electrocardiographic measures and type 2 diabetes, with the latter also influenced by parent of origin effects (^[@R16]--[@R20]^). Those associations were, however, all completely independent of any of the 6 top *KCNQ1* associated variants considered here (r^2^\<0.08). Furthermore, the 6 variants showed no significant association with any of 193 traits measured in the SardiNIA study participants (data not shown)(^[@R1],[@R21]^).

To evaluate the overall impact of known variants on the average short stature observed in Sardinia relative to other populations and to test the possibility that short stature might be selected for in this island population, we used polygenic height scores. These scores measure the total frequency of height-changing alleles in a population, weighing each allele by its effect size. A general North-to-South gradient for height in Europe due to directional selection has been reported (^[@R22],[@R23]^) with Sardinia as a significant outlier among the Human Genome Diversity Panel European populations ([URLs](#FN3){ref-type="fn"}). Consistent with these studies, we observed a significantly lower polygenic height score in Sardinia compared to other European populations examined in the 1000 Genomes project, including the Southern European Tuscans and Spanish ([Fig. 3](#F3){ref-type="fig"}). Adding our *KCNQ1* and *GHR* variants to the previously described 691 alleles (^[@R4]^), the polygenic score of Sardinians decreased by 3.8%. Overall, Sardinian scores are lower than would be expected compared to other European populations (p=1.62×10^−6^, −5.9cm relative to CEU, 1.6% average increase in frequency for height decreasing alleles, [Supplementary Fig.5](#SD1){ref-type="supplementary-material"}), even when calibrating for genome-wide patterns of differentiation due to genetic drift, suggesting that selection has played a role in decreasing height in Sardinia. The differences in height explained by the polygenic score are in accord with the observed \~10 cm of phenotypic differences between Sardinians and the other European populations.

We have also considered the possibility that Sardinians might have an additional contribution of reduced height due to the expression of recessively acting height-decreasing alleles exposed due to founder effects. However, the impact of elevated homozygosity among Sardinians on height appears to be small (0.129 s.d.) relative to the effects predicted by the polygenic score (0.910 s.d.) ([Supplementary Note](#SD2){ref-type="supplementary-material"}).

An example of low frequency allele affecting height was recently reported from the Icelandic population (^[@R24]^). However, our findings demonstrate for the first time that part of the missing heritability of human height can be attributable to rare variants involved in monogenic disorders, as shown by *GHR*, as well as by variants common in isolated populations but rare elsewhere, as exemplified by *KCNQ1*. Indeed, a shift toward higher frequencies for variants with large size effects observed in Sardinia (^[@R6],[@R25]^) -- and in this case the powerful height-decreasing variants \-- allowed us to detect, in a cohort of thousands of participants, associations that were missed in GWAS and meta-analyses of hundreds of thousands of individuals.

Intriguingly, the increased frequencies of height-decreasing alleles at *GHR* and *KCNQ1,* and especially the polygenic height scores in this population, are also consistent with the long-standing observation of an "island effect" in which many large animals become adaptively smaller on islands relative to their mainland counterparts (^[@R26]^). The extinct Sardinian mammoth (*Mammuthus lamarmorae*) and deer (*Megaloceros cazioti*) are two examples (^[@R27]^). One complication to assess this in in humans is that selection for decreased height likely began prior to the peopling of Sardinia among the early European farmer lineage (^[@R28]^) that is thought to have initially colonized the island(^[@R29]^), and Sardinians might have simply retained short stature that evolved earlier. However, we observe lower polygenic height scores in Sardinia even when compared with other populations with high proportions of early European Neolithic ancestry (Tuscans and Spanish)(^[@R30]^). Thus, selection for decreased height likely continued and was particularly strong in the lineage leading to modern Sardinians. One conjecture is that crop yields or other nutritional sources were limited in the restricted island environment, but exactly why selection for decreased height was acting among the Neolithic ancestors of the Sardinians, and likely intensified after the occupation of the island, remains an open and interesting question.

Online Methods {#S1}
==============

Research subjects {#S2}
-----------------

All individuals included in the study were of Sardinian origin and participate in a longitudinal study of age-related quantitative traits on the island (SardiNIA, [URLs](#FN3){ref-type="fn"}). The study involves four villages: Lanusei, Ilbono, Elini end Arzana, located in the Lanusei Valley(^[@R1],[@R21],[@R31]^). 6,148 volunteers have been described before (^[@R1]^) and an additional 773 individuals have been enrolled during the follow up stage of the project (^[@R6]^). 6,602 individuals had complete genotyping data. For analyses, we only included measurements for individuals at age \>20 years, and also discarded 4 subjects with Morquio Syndrome (OMIM \*607939), leading to a total of 6,307 samples.

All participants provided informed consent and studies were approved by the Local Research Ethic Committees (No 2009/0016600).

Genotyping methods, low-pass sample sequencing, variant calling, genotype imputation and GWAS analysis {#S3}
------------------------------------------------------------------------------------------------------

All SardiNIA individuals were typed with four Illumina Infinium arrays. Low pass sequencing, variant calling, genotype imputation and GWAS analysis was conducted as previously described (^[@R31]^).

GWA analysis {#S4}
------------

For our GWAS we tested association for the 11,826,948 imputed or genotyped variants that passed quality control filters \[MACH r^2^\>0.3 for MAF\>=0.01, r^2^\>=0.6 for MAF\<0.01 (^[@R31]^)\], assuming an additive model of inheritance and adjusting for age, age squared and gender as covariates and applying the inverse normal transformation to the residuals. Association was performed using EMMAX (^[@R32]^) as implemented in the software EPACTS ([URLs](#FN3){ref-type="fn"}), which accounts for relatedness and population structure using an empirical kinship matrix derived from genotype data. The genomic control inflation factor was λ=0.989, indicating no inflation of results.

Validation of imputation results by genotyping {#S5}
----------------------------------------------

GWAS identified three loci significantly associated with stature: the *GHR* gene, with top variant rs121909358; the *KCNQ1* gene, with 6 variants in LD ([Table 1](#T1){ref-type="table"}); and the *SMURF2* gene, with top variant rs143051029.

We validated imputation of rs121909358 genotypes by directly genotyping 2,818 samples with a TaqMan assay. Concordance between imputation and validation was 99.89%. At *KCNQ1*, two leading variants, rs67004488 and rs2075870, were present on the Cardio-Metabo Illumina chip, so that validation was not necessary. The third association at rs143051029 was evaluated with standard Sanger sequencing. We selected 96 samples for sequencing, including 4 imputed homozygotes, 22 imputed heterozygotes with uncertain allele dosages and 70 randomly selected samples. The variant, located in a complex region, did not pass validation due to the high mismatch rate (34.4%) between imputed genotypes and those validated by Sanger sequencing and was not further considered in analyses.

Conditional analysis {#S6}
--------------------

We conducted standard conditional analyses using EPACTS software for the two identified regions by including the top variants as covariates. We examined the 1Mb region around the top SNPs (rs121909358 for *GHR* and rs150199504 for *KCNQ1*). In both cases, the top variant completely explained the association at the two loci; none of the SNPs in the region passed the significance threshold after Bonferroni correction. The variant chr5:43229441, 540Kb away, from rs121909358, was fully explained by the effect of rs121909358 (p after conditional = 0.1).

Replication cohorts {#S7}
-------------------

We replicated findings in an independent cohort of 5,314 Sardinians and 19,053 non-Sardinian European samples. Details on genotyping and analyses are described in [Supplementary](#SM){ref-type="supplementary-material"}.

Characterization of the associated region on chromosome 5 {#S8}
---------------------------------------------------------

To visualize the haplotypes carrying the Laron variant ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}), we interrogated ±3Mb surrounding chr5:42689036 in 11 sequenced unrelated carriers of rs121909358. The analysis was performed using SelScan (^[@R33]^) and included 9,526 SNPs with MAF \>5% in Sardinia.

Parent-of-origin effects {#S9}
------------------------

For SNPs in the *KCNQ1* locus, we estimated parental origin of alleles for all individuals using Merlin (\--*best* option)(^[@R34]^). We then considered two separate variables, one for the maternal (G~m~) and one for the paternal (G~p~) allele, coded as 1 if the corresponding transmitted allele was the minor allele at the SNP, and 0 otherwise. Missing values were assigned to founders and other individuals for whom parental origin could not be defined unambiguously. Of consequence variables G~m~ and G~p~ were non-missing for 5,026 SardiNIA individuals and 4,666 OGP individuals. Two linear models were then used: $$\begin{matrix}
{Y \sim \beta_{0} + \beta_{1}G_{m} + \beta^{T}C} \\
{Y \sim \beta_{0} + \beta_{2}G_{p} + \beta^{T}C} \\
\end{matrix}$$ where Y denotes trait and C, other covariates. As both the SardiNIA and OGP studies consists of large families, the transmissions evaluated by G~p~ and G~m~ are not independent. We therefore tested the null hypothesis *β*~1~≠0 (for model 1) and *β*~2~≠0 (for model 2) by fitting a mixed linear regression model that accounts for familiar relatedness (*lmekin()* and *kinship()* functions in the coxme and kinship R packages). In the models, we used the same covariates and trait normalization procedure as in the GWAS analysis. We then assessed the hypothesis of heterogeneity of effects, *β*~1~ ≠ *β*~2,~ using Cochran's Q statistic. The test was carried out for all SNPs in the *KCNQ1* gene, and on SNP rs2075870 in the OGP cohort.

Population-level height polygenic score calculation and evaluation {#S10}
------------------------------------------------------------------

In the population genetic analyses, we focused on a subset of 1,081 unrelated sequenced individuals ([Supplementary Note](#SD2){ref-type="supplementary-material"}).

To investigate whether height-decreasing loci have been under selection in Sardinia, for each population *m*, we calculated the polygenic height score as $$Z_{m} = 2\sum\limits_{l = 1}^{L}\beta_{\iota}p_{\mathit{ml}}$$ where *β~l~* is the effect size of the height-increasing allele *l* and *p~ml~* is the frequency of allele *l* in population *m*. To avoid biases and to ensure uniformity of the source of effect size estimates, we used the effect size estimates from the Sardinian dataset regardless of whether the variant is significantly associated with height in this dataset. We first calculated the polygenic height score (Z*~m~*) based on the 691 height loci identified by the GIANT consortium (^[@R4]^) with effect sizes estimated in the Sardinian dataset and then added the two top variants reported, totaling 693 height alleles. To test if there were a signature of polygenic adaptation on height in Sardinia, we adopted a framework developed by Berg and Coop (^[@R23]^), which builds a multivariate normal model based on matched, presumably neutral variants, to account for relationships among populations ([Fig. 3](#F3){ref-type="fig"}). Populations with extreme polygenic scores relative to the expectation (pvalue = 0.01) are likely to have undergone selection. To construct a null distribution of frequencies needed for the multivariate normal framework, we obtained for each of the height loci all variants in the 1000 Genomes phase 3 European data with minor allele count +/− 10 counts (\~ 1% in frequency), B score (^[@R35]^) +/− 50 units, and local recombination rates +/− 0.5 cM/Mb. A random subset of 509,386 SNPs, representing 10% of the union of the matched SNPs, were then used as a set of matched SNPs for the analysis. Of note, we also repeated the calculation using effect sizes estimated by the GIANT consortium as well as using only a subset of 162 SNPs that are not subject to population stratification (^[@R22]^) ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}).
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======================
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![Regional association plots for *GHR* and *KCNQ1* locus\
a) *GHR* locus, the Y axis shows the association strength (−log10 pvalue) versus the genomic positions (hg19/GRCh37) around the most significant SNP (purple). Other SNPs in the region are color-coded to reflect their LD with the top SNP. Symbols reflect genomic functional annotation. Genes and the position of exons are shown below. b) Regional plot at the *KCNQ1* locus for the paternal and maternal effects respectively. The position of GWAS catalog SNPs ([URLs](#FN3){ref-type="fn"}) with the corresponding traits and the position of exons in the *KCNQ1* region are indicated below.](emss-64788-f0001){#F1}

![Worldwide frequency and LD pattern for the six top *KCNQ1* SNPs\
The figure illustrates the frequency (upper panel) and the pairwise LD matrix (lower panel) for the six top SNPs associated in Sardinia at the *KCNQ1* locus. Data are presented for 4 populations: a) Sardinia, b) Southern Europe, c) Northern Europe, d) East Asia. Matrix cells are colored according to the LD value: green if r^2^\>=0.7; yellow if 0.3\<= r^2^ \<0.7 ; red if r^2^\<0.3.](emss-64788-f0002){#F2}

![Polygenic score analysis for height\
Polygenic score based on the 2 top associated variants (rs121909358 and rs150199504) and the 691 height loci from GIANT for which the effect size in Sardinia and allele frequencies in 1000 Genomes phase 3 data are available. The black circles indicate the scale for display of p-values according to circle size. Abbreviations: SDI: SardiNIA cohort; IBS, TSI, GBR, CEU, and FIN: 1000 Genomes populations.](emss-64788-f0003){#F3}

###### Parental of origin effects at *KCNQ1*

The table summarizes the strongest results for the parental of origin association test at the *KCNQ1* locus (defined as pvalue\<1×10^−6^ in either the maternal or paternal tests for the assessed 500Kb region). At each SNP, we report in the column N the number of informative transmissions used (see Methods) and the association parameters obtained evaluating the minor allele i) without considering parent of origin, ii) when maternally inherited, and iii) paternally inherited. The last column reports the pvalue for heterogeneity between estimated paternal and maternal effects.

                                                  Both             Maternal      Paternal                                                  
  ------------- ------------ ----- ------- ------ ---------------- ------------- ---------------- ------------- ----------------- -------- -------------
  rs150199504   11:2814960   G/C   0.083   5059   −0.168 (0.039)   1.84×10^−5^   −0.315 (0.054)   5.56×10^−9^   −0.0032 (0.050)   0.9488   2.46×10^−5^
  rs143840904   11:2813322   T/C   0.094   5041   −0.152 (0.038)   4.58×10^−5^   −0.274 (0.050)   3.92×10^−8^   +0.0021 (0.049)   0.9653   7.55×10^−5^
  rs2075870     11:2790019   A/G   0.094   5044   −0.158 (0.038)   2.65×10^−5^   −0.273 (0.051)   6.97×10^−8^   −0.0172 (0.048)   0.793    0.0002
  rs149658560   11:2767262   A/G   0.076   5050   −0.161 (0.042)   1.01×10^−4^   −0.297 (0.058)   2.93×10^−7^   −0.0121 (0.052)   0.8183   0.0003
  rs12790610    11:2794998   G/A   0.095   5014   −0.165 (0.037)   1.02×10^−5^   −0.258 (0.051)   4.73×10^−7^   −0.044 (0.048)    0.3531   0.0023
  rs67004488    11:2787804   G/A   0.104   5026   −0.157 (0.036)   1.2×10^−6^    −0.244 (0.049)   5.21×10^−7^   −0.040 (0.047)    0.3875   0.0024
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